ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements with these filters
Arvaya Healthcare Ltd intimated a board meeting on November 13, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The trading window remains closed until 48 hours after results are declared.
Arvaya Healthcare's board approved the draft letter of offer for a rights issue of partly paid-up equity shares up to ₹210 Crore, plus a postal ballot. The board outcome's main decision is the rights issue, so it is classified as a capital raise step.
Arvaya Healthcare completed the acquisition of 100% equity in Sushodha Institute of Gastroenterology Private Limited on 1 November 2026. The target is now a wholly-owned subsidiary, with no consideration amount disclosed.
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
Arvaya Healthcare schedules a 4 November 2026 board meeting on rights issue, draft letter of offer and related party transactions. Agenda items remain proposed only.
Director Bidari Kotresh Anilkumar acquired 591,129 Arvaya Healthcare shares through a preferential offer. Holding rises to 4.45% from 3.58%.
Arvaya Healthcare allotted 38,71,854 equity shares at Rs.40 each to 47 SIGPL shareholders in a share swap. The allotment is valued at Rs.15.49 Crore.
Arvaya Healthcare will hold a board meeting on October 24, 2026, to consider a preferential allotment of 38.72 lakh equity shares to SIGPL shareholders.
Arvaya Healthcare Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Listing Regulations.
Arvaya Healthcare received BSE in-principle approval to issue 38,71,854 equity shares at Rs. 40 each. This preferential allotment totals Rs. 15.49 Crore.
Arvaya Healthcare Limited held its 41st Annual General Meeting on 21st September 2026, where members adopted financial statements and approved material related party transactions.
Arvaya Healthcare has incorporated a wholly-owned subsidiary, Arvaya Insurance Broking Private Limited, for an investment of ₹0.80 Crore. This entity will provide insurance broking services.
Arvaya Healthcare Limited has dispatched web links to shareholders for accessing the Notice of its 41st Annual General Meeting and the Annual Report.
Arvaya Healthcare filed its 41st Annual Report for FY 2025-26, including the notice for the Annual General Meeting scheduled on 21 September 2026.
Arvaya Healthcare Limited issued a Notice of its 41st Annual General Meeting to be held on 21 September 2026 via video conferencing. The agenda includes approval for material related party transactions.
Arvaya Healthcare Limited approved the acquisition of a Copyright and Intellectual Property portfolio from Defib Institute of Health Solutions LLP for a consideration of ₹10 Crores.
Arvaya Healthcare Limited scheduled a board meeting for August 26, 2026, to discuss a related party transaction regarding the acquisition of a business undertaking.
Arvaya Healthcare Limited submitted the voting results and the Scrutinizer's Report for its recent Postal Ballot. The company confirmed that all 6 resolutions were successfully passed.
Arvaya Healthcare Limited plans to incorporate a new wholly-owned subsidiary to operate in the insurance broking service sector. The company will hold 100% equity stake.
Arvaya Healthcare Limited has informed the exchange that the Statement of Deviation or Variation under Regulation 32 is not applicable for the quarter ended June 2026.
Arvaya Healthcare Ltd reported revenue from operations of ₹29.9 Cr and net profit of ₹0.5 Cr for Q1 FY27.